Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 6:23 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 100 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Fibrillation, Ventricular Clear all

Conditions: Paroxysmal Atrial Fibrillation, Persistent Atrial Fibrillation, Ventricular Arrhythmia
Interventions: Catheter ablation; Device
Lead sponsor: Heart Rhythm Clinical and Research Solutions, LLC; Other
Eligibility: 18 Years and older
Enrollment: 20,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2028
U.S. locations: 71
States / cities: Birmingham, Alabama • Mobile, Alabama • Chandler, Arizona + 64 more

Conditions: Tachycardia, Ventricular
Interventions: CyberHeart System; Device
Lead sponsor: Varian, a Siemens Healthineers Company; Industry
Eligibility: 60 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2023
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Ventricular Tachycardia, Ventricular Fibrillation, Sudden Cardiac Death, Heart Failure
Interventions: Not listed
Lead sponsor: Medtronic; Industry
Eligibility: Not listed
Enrollment: 1,778 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2019
U.S. locations: 72
States / cities: Birmingham, Alabama • Anchorage, Alaska • Gilbert, Arizona + 69 more

Conditions: Atrial Fibrillation, Supraventricular Arrhythmia, Ventricular Arrhythmias and Cardiac Arrest, Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Interventions: Medtronic LINQ-2 Insertable Cardiac Monitor (ILR); Device
Lead sponsor: Northwell Health; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2030
U.S. locations: 1
States / cities: New Hyde Park, New York

Conditions: Ventricular Fibrillation
Interventions: Simulation-Based Training; Behavioral
Lead sponsor: St. Luke's-Roosevelt Hospital Center; Other
Eligibility: 18 Years and older
Enrollment: 157 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: New York, New York

Conditions: Atrial Fibrillation, Heart Failure
Interventions: Ranolazine, Placebo; Drug
Lead sponsor: Intermountain Health Care, Inc.; Other
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Murray, Utah

Conditions: Heart Failure, Ventricular Dysfunction, Sudden Death, Sudden Cardiac Arrest, Ventricular Tachycardia, Ventricular Fibrillation
Interventions: wearable defibrillator (LifeVest); Device
Lead sponsor: Zoll Medical Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2017
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Hyperkalemia
Interventions: Sodium Zirconium Cyclosilicate (SZC), SZC Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 2,690 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 57
States / cities: Huntsville, Alabama • Mesa, Arizona • Bakersfield, California + 47 more

Conditions: Ventricular Arrhythmia
Interventions: Eleclazine, Placebo to match eleclazine; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 313 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 37
States / cities: Mesa, Arizona • Long Beach, California • Los Angeles, California + 32 more

Conditions: Cardiac Arrhythmia, Atrial Fibrillation, Ventricular Arrythmia, Premature Ventricular Complexes Multiple, Ventricular Tachycardia, Ventricular Fibrillation, Premature Atrial Complex, Atrioventricular Reentrant Tachycardia
Interventions: Cardiac ablation procedure; Device
Lead sponsor: Vektor Medical; Industry
Eligibility: 22 Years to 100 Years
Enrollment: 225 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 4
States / cities: Charleston, California • La Jolla, California • San Diego, California + 1 more

Conditions: Heart Rate and Rhythm Disorders
Interventions: Metoprolol, Diltiazem; Drug
Lead sponsor: Antonios Likourezos; Other
Eligibility: 18 Years and older
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Brooklyn, New York

Conditions: Sudden Cardiac Death, Ventricular Tachycardia, Ventricular Fibrillation, Cardiomyopathy
Interventions: Cardiac Sympathetic Denervation (CSD), Routine Care; Procedure · Drug
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 3
States / cities: Los Angeles, California • Portland, Oregon • Nashville, Tennessee

Conditions: Atrial Fibrillation New Onset, Hemorrhage, Prolonged QTc Interval, Ventricular Tachycardia, Medical Care; Complications, Late Effect of Complications
Interventions: Ranolazine, Placebo; Drug
Lead sponsor: Northwell Health; Other
Eligibility: 18 Years and older
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Staten Island, New York

Conditions: Sudden Cardiac Death, Ventricular Fibrillation, Ventricular Tachycardia, Ventricular Dysfunction, Myocardial Ischemia
Interventions: wearable defibrillator (LifeVest); Device
Lead sponsor: Zoll Medical Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 5
States / cities: Sacramento, California • Atlanta, Georgia • Takoma Park, Maryland + 2 more

Conditions: Arrhythmia, Tachycardia, Ventricular, Ventricular Fibrillation
Interventions: SSR149744C; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 21 Years and older
Enrollment: 153 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Ventricular Tachycardia, Ventricular Fibrillation
Interventions: ICD; Device
Lead sponsor: Medtronic Cardiac Rhythm and Heart Failure; Industry
Eligibility: 18 Years and older
Enrollment: 1,326 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 44
States / cities: Little Rock, Arkansas • Fountain Valley, California • Poway, California + 41 more

Conditions: Hypertrophic Cardiomyopathy
Interventions: Not listed
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 260 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Ventricular Tachycardia, Ventricular Fibrillation
Interventions: Implantable Cardioverter Defibrillator (ICD); Procedure
Lead sponsor: OhioHealth; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Ventricular Arrythmia, Ventricular Fibrillation, Ventricular Tachycardia
Interventions: Atala™ lead and EV-ICD Pulse Generator; Device
Lead sponsor: AtaCor Medical, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 280 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 27
States / cities: Scottsdale, Arizona • Jonesboro, Arkansas • La Jolla, California + 23 more

Conditions: Cardiac Arrest
Interventions: amiodarone, Lidocaine, Normal saline; Drug · Other
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 3,024 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 7
States / cities: Birmingham, Alabama • San Diego, California • Portland, Oregon + 4 more

Conditions: Cardiovascular Diseases, Heart Diseases, Myocardial Infarction, Coronary Disease, Arrhythmia, Ventricular Fibrillation
Interventions: PCI, Optimal Medical Therapy; Procedure · Drug
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: Not listed
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2006
U.S. locations: 1
States / cities: Stony Brook, New York

Conditions: Atrial Fibrillation, Ventricular Tachycardia, Premature Ventricular Contraction
Interventions: Not listed
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Cardiac Arrest
Interventions: Echocardiography, Electrocardiogram (ECG); Diagnostic Test
Lead sponsor: Romolo Gaspari; Other
Eligibility: 18 Years and older
Enrollment: 813 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 6
States / cities: Hartford, Connecticut • Lebanon, New Hampshire • Stony Brook, New York + 3 more

Conditions: Other Intraoperative Cardiac Functional Disturbances During Cardiac Surgery
Interventions: Lidocaine, Amiodarone, Placebo; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 342 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Rochester, Minnesota

Search by objective public record fields.

Real-world Experience of Catheter Ablation for the Treatment of Arrhythmias

CyberHeart's Cardiac Arrhythmia Ablation Treatment: Patients With Refractory Ventricular Tachycardia/Fibrillation

DF4 Connector System Post-Approval Study

Implanted Loop Recorders for Detection and Management of Arrhythmia With Bruton Tyrosine Kinase Inhibitors

Physicians in Training and Critical Care Nurses Performance in Medical Code Events: Effect of Simulation-Based Training

The Use of Ranolazine for Atrial Fibrillation and Diastolic Heart Failure

Study of the Wearable Defibrillator in Heart-Failure Patients

Effect of Sodium Zirconium Cyclosilicate on Arrythmia-related Cardiovascular Outcomes in Participants on Chronic Hemodialysis With Recurrent Hyperkalemia (DIALIZE-Outcomes)

Evaluating Ventricular Arrhythmia in Subjects With Implantable Cardioverter Defibrillator or Cardiac Resynchronization Therapy-Defibrillator

Vektor vMap™ Clinical Validation Study

Comparison of Diltiazem and Metoprolol in the Management of Acute Atrial Fibrillation or Atrial Flutter

Cardiac Sympathetic Denervation for Prevention of Ventricular Tachyarrhythmias

Randomized Double Blind Control Trial on Effects of Ranolazine on New Onset Atrial Fibrillation

LifeVest Post-CABG Registry

Double Blind Placebo Controlled Dose Ranging Study of the Efficacy and Safety of SSR149744c 100 or 300 mg for the Prevention of ventrICular ARrhythmia-triggered Icd interventiOnS

INSIGHTS ICD Registry

A Prospective Incident Study of Arrhythmias in Hypertrophic Cardiomyopathy

Effect of Right Ventricular Lead Position on Defibrillation Threshold

Parasternal Extravascular ICD System Pivotal Clinical Investigation (ALARION EV) Study

Amiodarone, Lidocaine or Neither for Out-Of-Hospital Cardiac Arrest Due to Ventricular Fibrillation or Tachycardia

Electrophysiological Effects of Late PCI After MI

Defining the Risk of Ventricular Tachycardia in Genetic Cardiomyopathies

Vfib by ECG or Echo During Cardiac Arrest

Amiodarone for the Prevention of Reperfusion Ventricular Fibrillation